Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Design Consideration01:22

Design Consideration

575
Designing a structure involves a series of considerations, primarily the material's ultimate strength, calculated through tests that measure changes under increased force until the material reaches its breaking point or limit. The ultimate load, where the material breaks, is divided by its original cross-sectional area, resulting in the ultimate normal stress or strength. The ultimate shearing stress is another significant factor taken into account.
The factor of safety is another key...
575
Transmission Line Design Considerations01:23

Transmission Line Design Considerations

630
Aluminum has become the material of choice for overhead transmission lines, surpassing copper due to its abundance and cost-effectiveness. The most prevalent type is the aluminum conductor, steel-reinforced (ACSR), which combines aluminum strands around a steel core. Other variants include all-aluminum conductors (AAC), all-aluminum alloy conductors (AAAC), aluminum conductor alloy-reinforced (ACAR), and aluminum-clad steel conductors. Advanced designs, such as aluminum conductors with steel...
630
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

4.9K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.9K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

5.1K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
5.1K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.4K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.8K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.

Technology in cancer research & treatment·2026
Same author

Integrative Oncology in Practice: Moving the SIO-ASCO Guidelines From Evidence to Implementation.

Seminars in radiation oncology·2026
Same author

Integrative Oncology for Prostate Cancer: A Narrative Review.

Seminars in radiation oncology·2026
Same author

Developing a Preliminarily Validated Competency-Based Integrative Oncology Training Questionnaire.

Journal of pain and symptom management·2026
Same author

Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.

Journal of the National Cancer Institute·2026
Same author

Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC.

International journal of radiation oncology, biology, physics·2026

Related Experiment Video

Updated: Jan 31, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Brian P Hobbs1, Pedro C Barata2,3, Yada Kanjanapan4,5

  • 1Quantitative Health Sciences and Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

Journal of the National Cancer Institute
|December 19, 2018
PubMed
Summary

Seamless first-in-human (FiH) trials can expedite drug approval but require careful planning. While efficient, these innovative designs must uphold ethical, scientific, and statistical standards for patient safety and efficacy.

More Related Videos

Author Spotlight: Enhancing Accuracy and Reproducibility in Whole Bone Bending Tests
04:20

Author Spotlight: Enhancing Accuracy and Reproducibility in Whole Bone Bending Tests

Published on: September 1, 2023

1.4K
Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI
10:35

Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI

Published on: June 3, 2013

33.3K

Related Experiment Videos

Last Updated: Jan 31, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Author Spotlight: Enhancing Accuracy and Reproducibility in Whole Bone Bending Tests
04:20

Author Spotlight: Enhancing Accuracy and Reproducibility in Whole Bone Bending Tests

Published on: September 1, 2023

1.4K
Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI
10:35

Best Current Practice for Obtaining High Quality EEG Data During Simultaneous fMRI

Published on: June 3, 2013

33.3K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Drug Development

Background:

  • Traditional drug development follows sequential phases (dose, safety, activity, benefit).
  • Innovations aim to consolidate phases and accelerate patient accrual using seamless trial designs.
  • Seamless first-in-human (FiH) trials present opportunities and challenges regarding objectives, statistical plans, and oversight.

Purpose of the Study:

  • To evaluate the opportunities and challenges of seamless FiH trial designs.
  • To encourage the responsible use of seamless trial designs in early-phase drug development.
  • To analyze the characteristics and outcomes of seamless FiH trials presented at ASCO meetings.

Main Methods:

  • A review of abstracts from American Society of Clinical Oncology (ASCO) annual meetings (2010-2017).
  • Included FiH trials enrolling at least 100 patients.
  • Identified and analyzed seamless trial designs among 1786 early-phase trials.

Main Results:

  • Fifty-one seamless trials (2.9%) investigated 50 new drugs, enrolling 57,559 patients (14.6% of total).
  • Seamless trials featured a median of 3 expansion cohorts.
  • The risk of grade 3-4 adverse events was 49.1%; seven studies reported toxic deaths.

Conclusions:

  • Rapid expansion in FiH trials can accelerate drug approval and patient access.
  • Seamless designs necessitate adherence to ethical, scientific, and statistical standards.
  • Protocols require prospectively planned efficacy analyses in defined cohorts for accelerated approval.